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Background: Infants are vulnerable to zinc deficiency. Thus, abnormally low breast 
milk zinc levels cause transient neonatal zinc deficiency (TNZD) in breast-fed infants. 
TNZD has been considered to be rare because of a paucity of citations in the published 
literature. However, recent studies of affected mothers identified four missense 
mutations in the solute carrier family 30 member 2 gene (SLC30A2), which encodes the 
zinc transporter, ZnT2. 
Methods: Genetic analyses of SLC30A2/ZnT2 in three Japanese mothers secreting 
low-zinc milk (whose infants developed TNZD) were performed. The effects of 
identified mutations were examined in a cell-based assay. Furthermore, 31 single 
nucleotide polymorphisms (SNPs) in SLC30A2/ZnT2 were evaluated for their potential 
involvement in low-zinc levels in milk. 
Results: Each mother had a different novel heterozygous mutation in SLC30A2/ZnT2. 
One mutation reduced splicing efficiency of the SLC30A2/ZnT2 transcript and all ZnT2 
mutants were defective in zinc transport and were unstable in cells. Moreover, four 
SNPs caused a significant loss of zinc transport activity, similar to that in 
disease-causing ZnT2 mutants. 
Conclusion: Our results indicate that many SLC30A2/ZnT2 mutations cause or 
potentially cause TNZD. Genetic information concerning TNZD pathogenesis is limited, 




Approximately 10% of all human proteins are thought to be zinc-binding, and zinc 
plays a pivotal role as a structural, catalytic, and signaling component of proteins in 
numerous physiological processes (1,2). Thus, zinc in breast milk is essential for the 
normal growth and development of infants (3,4). To meet infants’ requirements, large 
amounts of zinc (1–3 mg/day) are secreted into breast milk during lactation, particularly 
in the first 3 months after birth (5-7). This is considerably higher than levels in the 
maternal serum (8). A reduction in the level of breast milk zinc causes breast-fed infants 
to develop zinc deficiency, which presents with a broad range of defects, such as 
erythematous and erosive dermatitis, persistent diarrhea, hair loss, immune system 
dysfunction, and retardation in physical development (1,8-17). It is well known that the 
demand for zinc increases rapidly in thriving preterm infants (18,19), and thus a risk of 
zinc deficiency increases in preterm infants (20,21). However, symptomatic zinc 
deficiency has been found even in full-term infants, mostly because of inherited 
disorders. 
Inherited zinc deficiency disorders in breast-fed full-term infants are classified 
into two types: acrodermatitis enteropathica (AE) [Online Mendelian Inheritance in 
Man (OMIM) 201100] and transient neonatal zinc deficiency (TNZD) (OMIM 608118) 
(1,16,17,19,22,23). AE is caused by the intestinal malabsorption of zinc, and as a result 
infants still suffer from zinc deficiency after weaning. In contrast, TNZD is caused by 
low zinc concentrations in breast milk; thus, infants develop the symptoms of zinc 
deficiency only during breast-feeding. TNZD, as its name suggests, does not reoccur 
after weaning, and is therefore definitively different from AE. Mutations in zinc 
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transporter genes have been identified to be responsible for each of these disorders 
(1,16,17); AE is caused by mutations in the solute carrier family 39 member 4 gene 
(SLC39A4) [also known as the Zrt and Irt-like protein 4 gene (ZIP4)], while TNZD is 
caused by mutations in SLC30A2 [also known as the Zn transporter 2 gene (ZnT2)]. 
ZIP4 is a zinc importer on the apical membrane of enterocytes, and is essential for zinc 
absorption. Thus, disease-causing ZIP4 mutants lead to severe zinc deficiency. 
Conversely, ZnT2 mobilizes zinc into the secretory vesicles in mammary epithelial cells, 
which are thought to be released into the alveolar lumen, and then secreted into breast 
milk during lactation (5,6). Hence, disease-causing SLC30A2/ZnT2 mutations cause 
mothers to produce zinc-deficient breast milk, and infants fed with this milk acquire 
severe zinc deficiency. 
Over 30 mutations in SLC39A4/ZIP4 have been found to cause AE; however, 
there is a paucity of citations related to TNZD in the literature, leading to the 
assumption that TNZD is extremely rare. Indeed, it has not been possible to define the 
frequency of this disorder (24). However, in the past 8 years, at least 20 different 
Japanese case reports and abstracts have presented zinc deficiency in full-term infants 
caused by zinc-deficient breast milk (Supplemental Table S1 (online)). Since the first 
finding of a missense mutation in SLC30A2/ZnT2 as a genetic cause of TNZD by 
Kelleher’s group (10), one nonsense and four missense mutations have been identified 
in mothers secreting zinc-deficient breast milk, whose infants developed TNZD (12-15). 
In this paper, we analyzed genomic DNA from three of the mothers included in the 20 
Japanese reports, and identified three novel loss-of-function SLC30A2/ZnT2 mutations. 
Moreover, we report here that four single nucleotide polymorphisms (SNPs) in 
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SLC30A2/ZnT2, which result in amino acid substitutions, cause ZnT2 to lose its zinc 
transport activity. Our results provide crucial genetic information concerning TNZD 
pathogenesis in breast-fed infants. 
 
RESULTS 
Three Novel, Missense, Loss-of-Function, Heterozygous SLC30A2/ZnT2 Mutations  
For this study, we recruited three Japanese mothers who produced zinc-deficient breast 
milk and whose breast-fed infants suffered from severe zinc deficiency (Supplemental 
Table S2 (online)). We analyzed all SLC30A2/ZnT2 exons and their flanking regions, 
including splice sites, in each mother and found three novel heterozygous missense 
mutations: c.838G>A at the end of exon 6 (with reference to the adenine of the start 
methionine as +1), c.935C>T (p.T312M) in exon 7, and c.1063G>C (p.E355Q) in exon 
8 (Figure 1a and b and Supplemental Table S2 (online)). The c.838G>A mutation (a G 
to A substitution) conserved the consensus sequence of the splice site (human U2-type 
intron) (25), but our reverse transcriptase (RT)-PCR analysis using ZnT2 cDNA 
constructs containing intron 6 (Figure 2a) indicated that it reduced the splicing 
efficiency of the ZnT2 transcript to almost one-fourth that of the wild-type sequence 
(Figure 2b). Thus, the c.838G>A mutation results in reduced splicing efficiency of 
intron 6, and causes substitution p.G280R in the ZnT2 protein when intron 6 is spliced 
out. 
 
Evaluation of Zinc Transport Activity of the Three Novel ZnT2 Mutants found in 
Japanese Mothers 
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We previously evaluated the defects of four TNZD missense ZnT2 mutations [two of 
which we identified (W152R and S296L) (13) and two of which were found by others 
(H54R and G87R) (10,12)], using genetically engineered mutant (ZnT1−/−MT−/−ZnT4−/−) 
cells (13). These cells show a zinc-sensitive phenotype, which is reversed by the stable 
expression of zinc-transport competent ZnT2. Similar to the well-established mutant 
BHK cell line (26), our cell system is simple but useful for the examination of ZnT2 
zinc transport activity. 
In the present study, the stable expression of G280R, T312M, and E355Q 
ZnT2 mutants failed to reverse the zinc-sensitive phenotype of ZnT1−/−MT−/−ZnT4−/− 
cells, suggesting that these mutants have impaired zinc transport activity (Figure 3a). 
Moreover, lack of zinc transport activity in each mutant was confirmed using a 
fluorescent zinc-selective probe, Zinpyr-1 (27). Zinpyr-1 can detect 
vesicular/compartmentalized zinc; therefore, in this study its fluorescence reflects zinc 
transported by ZnT2 from the cytosol into the vesicles. Zinc mobilized into the 
secretory vesicles by ZnT2 is thought to be released into the alveolar lumen in lactating 
mammary glands (5, 6). The cells used above were cultured in the presence of 30 µM 
ZnSO4 for 48 h, loaded with Zinpyr-1, and the fluorescence intensity was analyzed by 
flow cytometry. Wild-type (WT) ZnT2 expression increased the fluorescence intensity 
of Zinpyr-1 in ZnT1−/−MT−/−ZnT4−/− cells cultured in the presence of 30 µM ZnSO4 
(Figure 3c). However, the expression of G280R, T312M, or E355Q ZnT2 mutants 
produced no increase in fluorescence intensity (Figure 3c). Taken together, these 
findings indicate that all three mutations result in a lack of zinc transport activity. 
As detected in other previously reported TNZD-causing mutants (13), the 
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protein stability of these three ZnT2 mutants was significantly reduced (Figure 4a). 
Moreover, immunoprecipitation analysis indicated that all three ZnT2 mutants can form 
dimers with WT ZnT2 (Figure 4b), suggesting that they may impair the zinc transport 
functions of WT ZnT2 in a dominant negative manner. These results indicate that 
SLC30A2/ZnT2 c.838G>A (p.G280R), c.935C>T (p.T312M), and c.1063G>C 
(p.E355Q) mutations cause loss-of-function, and that haploinsufficiency or possible 
dominant negative effects result in low levels of zinc in the breast milk of affected 
mothers. Reduced splicing efficiencies may also contribute to pathogenesis in the 
c.838G>A mutation case.  
 
Evaluation of SNPs on ZnT2 Zinc Transport Function 
We next evaluated the effects of SLC30A2/ZnT2 SNPs archived in the NCBI public 
database (http://www.ncbi.nlm.nih.gov/snp) on ZnT2 zinc transport activity to 
determine their potential involvement in the pathogenesis of TNZD. For a first 
evaluation, we randomly selected 31 SLC30A2/ZnT2 SNPs (all of which are shown to 
be minor alleles with frequencies up to 0.0036) (Table 1 and Supplemental Table S3 
(online)) that cause amino acid substitutions, and investigated their effects in viability 
assays using ZnT1−/−MT−/−ZnT4−/− cells. We found that four SNPs: rs148861822, 
c.542C>T (p.T181M); rs200520278, c.567C>A (p.N189K); rs201084300, c.698G>A 
(p.G233D); and rs377192955, c.1063G>A (p.E355K), failed to reverse the 
zinc-sensitive phenotype of ZnT1−/−MT−/−ZnT4−/− cells (Table 1 and Figure 3b). Flow 
cytometry analysis using Zinpyr-1 confirmed that these SNPs caused ZnT2 to lose zinc 
transport activity (Figure 3d), as in the case of TNZD-causing mutations (see Figure 3c). 
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These SNP mutants were all destabilized but could form dimers with WT ZnT2, similar 
to the TNZD-causing mutants described above (Figure 5a and b). These results suggest 
that the four SNPs cause mothers to produce low-zinc breast milk and thus may be 
involved in TNZD pathogenesis in breast-fed infants. For another 27 SNP mutants, we 
found minimal defects in the cell viability assay (Supplemental Table S3 (online)); 
therefore, these SNPs are unlikely to be involved in TNZD pathogenesis. 
 
DISCUSSION 
We are aware of at least 20 different reports and abstracts of transient zinc deficiency in 
full-term breast-fed infants published in the past 8 years (2007–2014) (Supplemental 
Table S1 (online)). Moreover, 24 case reports of this condition were presented in 
domestic Japanese pediatrics and dermatology journals between 1981 and 2006 (28). In 
all cases from 2007–2014 and in 17 of 24 cases from 1981–2006, zinc deficiency in 
breast-fed infants was attributed to low levels of zinc in the mother’s breast milk, and 
symptoms were cured by zinc supplementation therapy and did not reoccur, which is 
typical for TNZD. Considering the paucity of TNZD-related publications in 
international journals (24), the frequency of reported TNZD cases in Japan is of interest.  
At present, over 50% of mothers in Japan are estimated to be exclusively 
breast-feeding their infants, which is a significant increase compared with the number in 
2000 (about 40%) (29). This may explain the recent increase in case reports, because 
the use of fortified formulas would mask the progression of TNZD and impact on 
apparent rates of TNZD. Additionally, pediatricians in Japan have recently learned that 
infant dermatitis is caused by zinc deficiency (30). In most cases, TNZD is first 
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suspected by low alkaline phosphatase activity (28,31,32), which is routinely measured 
as a marker of liver function, and which is significantly dependent on zinc levels (33). 
In infants where low alkaline phosphatase activity is detected, prompt measurement of 
zinc levels in the infant’s serum and the mother’s breast milk would be useful to 
facilitate early TNZD diagnosis.  
In this study, we identified three novel, heterozygous SLC30A2/ZnT2 
mutations in three affected Japanese mothers: c.838G>A in exon 6, c.935C>T in exon 7, 
and c.1063G>C in exon 8. The c.838G>A mutation reduced splicing efficiency, and also 
caused a G280R substitution, which resulted in the loss of zinc transport activity. 
Moreover, T312M (c.935C>T) and E355Q (c.1063G>C) substitutions in SLC30A2/ZnT2 
resulted in loss-of-function. The three novel TNZD-causing mutations presented here 
bring the total of TNZD-causing mutations identified to date to eight. There is, therefore, 
a larger variety, and a higher frequency, of TNZD-causing SLC30A2/ZnT2 mutations 
than previously thought. Including the three cases in this study, all cases have reported 
heterozygous mutations in SLC30A2/ZnT2, except for one case with compound 
heterozygous mutations (13), suggesting that TNZD is caused by haploinsufficiency or 
dominant negative mechanisms (10,12-15).  
Consistent with affected mothers in previous reports (10,12-15), the three 
affected mothers in this study produced breast milk with >70% reduced zinc levels (see 
Supplemental Table S2 (online)). Moreover, in the 20 recent reports and abstracts of 
TNZD in Japan, breast milk zinc levels were decreased by >60% in all mothers 
(Supplemental Table S1 (online)). However, comparison of zinc levels at the time of 
TNZD diagnosis with average normal zinc levels at the corresponding time point during 
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lactation is unreliable for setting a threshold for TNZD pathogenesis, because zinc levels 
in breast milk vary considerably among mothers (34,35). Furthermore, the onset or 
progression of disease is likely to depend on the health condition of the infant, including 
the zinc pool in the body. Thus, the relationship between zinc levels in breast milk and 
the onset and progression of TNZD needs to be more extensively investigated in future 
studies. In the 20 recent reports and abstracts, the maximum zinc level was 32 µg/dL at 5 
months (Supplemental Table S1 (online)). Accordingly, a breast milk zinc content of 32 
µg/dL or lower may be an index for the onset and progression of TNZD symptoms.  
Many SNPs have been identified in SLC30A2/ZnT2, and several have been 
well characterized; for example, two SNPs, rs35235055 (c.68T>C causing L23P) and 
rs35623192 (c.1018C>T causing R340C), have been proposed to compromise zinc 
secretion in breast milk (36). In this study, we identified a further four SNPs that result 
in the loss of zinc transport activity, suggesting their potential involvement in low levels 
of zinc secretion into milk. Of these, the position of rs377192955 (c.1063G>A causing 
E355K) is identical to that of the TNZD mutation found in patient 3 (E355Q), 
indicating that our SNP evaluation yielded reliable results. Because the molecular basis 
of ZnT2 functions has recently been revealed (37,38), detailed characterization of each 
SLC30A2/ZnT2 SNP and the relationship between each SLC30A2/ZnT2 SNP and the 
effects on zinc transport activity would be beneficial for understanding TNZD 
pathogenesis. Further research is needed to determine if SLC30A2/ZnT2 SNPs can cause 
subtler or minor adverse effects. 
In conclusion, infant zinc nutrition is of particular importance for healthy 
growth and development, and zinc levels in breast milk should be of primary concern. 
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TNZD occurs through a deficiency of zinc levels in the mother’s breast milk, which is 
controlled by ZnT2. Determination of the TNZD frequency is difficult to estimate 
because it may be masked by the use of fortified formulas. Moreover, there is a paucity 
of genetic information concerning TNZD pathogenesis (24). However, our present 
results provide crucial genetic information about TNZD pathogenesis, and indicate that 
the frequency of TNZD may be higher than previously thought. These findings provide 
helpful information to support the normal growth and development of breast-fed infants. 
 
METHODS 
Three full-term breast-fed infant patients were diagnosed with zinc deficiency by their 
pediatricians based on clinical presentations. Each infant showed low serum zinc levels 
and presented with symptoms of zinc deficiency at 1.5–5 months. Zinc levels in the 
breast milk of all three mothers were also lower than the normal level expected during 
lactation (35,39); however, their serum zinc levels were normal. Patient 1 was a 
full-term female (gestational age, 40 weeks; birth weight, 2,630 g), who had been 
exclusively fed on breast milk from her mother. Dermatitis was present from 3 months 
of age. Her serum zinc level was significantly low (13 µg/dL at 4 months; normal level: 
70–120 µg/dL). At 4 months, her mother’s breast milk zinc level of 10 µg/dL was lower 
than the normal level of 80±30 µg/dL at 4–6 months. Clinical information for patients 2 
and 3 has been reported in domestic Japanese journals (31,32), and the clinical data of 
all patients are summarized in Supplemental Table S2 (online). All infants were given 
Polaprezinc [INN: (C9H12N4O3Zn)n] oral zinc replacement therapy, which promptly 
eliminated symptoms.  
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Sequencing SLC30A2/ZnT2  
Genomic DNA was isolated from the mothers’ whole blood using a QIAamp DNA 
Blood Midi Kit (Qiagen, Hilden, Germany) or a NucleoSpin Blood Kit 
(Macherey-Nagel, Düren, Germany). All exons containing coding regions (including 
splice sites) of SLC30A2/ZnT2, and the sequence in and around the promoter regions of 
SLC30A2/ZnT2 were directly sequenced in both directions, using fragments amplified 
from the isolated genomic DNA. Primer information is described in our previous study 
(13). 
 
Plasmid Construction, and Transient and Stable Transfection 
ZnT2 cDNA expression plasmids containing intron 6, with G (WT) or A (mutant) at 
position c.838 at the 3′ end of exon 6 were constructed (see Figure 2a). DT40 cells were 
transiently transfected with each plasmid as described previously (40). For 
normalization of transient transfection efficiency, Renilla luciferase was used, and the 
activity ratio of each transfection was within 1.15. To evaluate zinc transport activity in 
each ZnT2 mutant in stable transformants, we introduced mutations into ZnT2 cDNA as 
described previously (13). DNA transfection to establish cells stably expressing WT 




Total RNA was isolated from transiently transfected DT40 cells using Sepasol I 
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(Nacalai Tesque, Kyoto, Japan). Reverse transcription was performed using ReverTra 
Ace (Toyobo, Osaka, Japan) and 1 µg total RNA as a template. PCR was performed 
using KOD Plus polymerase (Toyobo). The amplified products of spliced (281 bp) or 
unspliced (330 bp) forms of ZnT2 mRNA were electrophoresed on a 3% agarose gel 
and stained with ethidium bromide. For semi-quantitative RT-PCR, products amplified 
after 33–35 cycles were quantified by densitometry using ImageQuant (GE Healthcare, 
Waukesha, WI). Primer sequences are listed in Supplemental Table S4 (online). 
 
Evaluation of Zinc Transport Activity of ZnT2 Proteins Based on a Viability Test 
of Zinc-Sensitive Cells Against High Extracellular Zinc Concentrations 
DT40 cells deficient in ZnT1, ZnT4, and metallothionein genes (MT) 
(ZnT1−/−MT−/−ZnT4−/− cells) were cultured as described previously (13,40). 
ZnT1−/−MT−/−ZnT4−/− cells fail to grow in the presence of 60 µM or more ZnSO4, 
whereas ZnT1−/−MT−/−ZnT4−/− cells stably expressing zinc-transport competent ZnT2 
can grow in a similar manner to parental cells. Thus, cell viability in high levels of 
extracellular zinc reflects the zinc transport activity of ZnT2 (13,40). Cell viability was 
determined using the alamarBlue assay (Trek Diagnostic Systems, Westlake, OH). 
 
Evaluation of Zinc Transport Activity of ZnT2 Proteins Using a Fluorescent 
Zinc-Selective Probe and Flow Cytometry 
ZnT1−/−MT−/−ZnT4−/− cells stably expressing each ZnT2 protein were grown in the 
presence or absence of 30 µM ZnSO4 for 48 h and washed once in phosphate-buffered 
saline (PBS). Cells were then treated with 5 µM Zinpyr-1 ester (Santa Cruz 
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Biotechnology, Santa Cruz, CA) for 30 min at room temperature. After extensive 
washing with PBS containing 20 mM EDTA to remove extracellular zinc, the cells were 
resuspended in PBS containing 1% bovine serum albumin, and were subjected to flow 
cytometric analysis using a BD Accuri C6 flow cytometer (BD Biosciences, Ann Arbor, 
MI). Histograms were overlaid according to the log10 ratio increase of Zinpyr-1 
fluorescence in zinc-supplemented (30 µM ZnSO4) conditions relative to normal 
conditions using Cytobank (http://www.cytobank.org/). The fluorescence intensity of 
Zinpyr-1 increases with zinc accumulation in vesicles and intracellular compartments 
mobilized from the cytosol, and thus reflects the zinc transport activity of ZnT2 proteins 
expressed in ZnT1−/−MT−/−ZnT4−/− cells in this study. 
 
Evaluation of Stability of Mutant ZnT2 Proteins 
Cells expressing WT or mutant ZnT2 were treated with cycloheximide to block further 
protein synthesis and collected periodically over 4–8 h. The collection of cells at 8 h 
was performed when the band intensity of the ZnT2 mutant protein was more than 50% 
at 2 h after treatment, compared with that at 0 h. Total cell lysates were prepared from 
cells and subjected to immunoblotting to monitor ZnT2 levels as described previously 
(13). The following antibodies were used: anti-ZnT2 (1:4000 dilution) (13), or 
anti-tubulin (1:20000; Sigma, St. Louis, MO). The ZnT2 band intensities are the 
averages of three independent experiments, and are shown as the percentage of the 
intensity at 0 h (T0) after normalization against tubulin at each time point. Fluoroimages 
were obtained using a LAS1000 Plus image analyzer (Fujifilm, Tokyo, Japan). 
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Densitometry quantification of ZnT2 protein was performed using ImageQuant (GE 
Healthcare). 
 
Evaluation of Dimerization by Immunoprecipitation 
Dimerization of ZnT2 was examined by immunoprecipitation as described previously 
(13). Briefly, membrane factions prepared from cells stably expressing both HA- or 
FLAG-tagged WT and mutant ZnT2 were incubated with anti-FLAG M2 (1:200 
dilution, Sigma) or anti-HA HA-11 (1:200 dilution, Covance, Emeryville, CA) 
antibodies in NP-40 buffer for 1 h. Then, 10 µl of Protein G-Sepharose beads (GE 
Healthcare) were added and incubated for 2 h. Immunoprecipitates were then subjected 
to immunoblotting with polyclonal anti-HA (1:4000; MBL, Nagoya, Japan) or 
polyclonal anti-FLAG (anti-DDDDK; 1:4000; MBL) antibodies. To estimate the 
amount of WT and mutant ZnT2 proteins in samples, 10% of each aliquot was 
subjected to immunoblot analysis (input panels) using an anti-calnexin (CNX) antibody 
(1:4000 dilution; Stressgen, Ann Arbor, MI). Experiments were performed three times, 
giving similar results.  
 
Statistical Analyses 
All data are depicted as the mean ± SD. Statistical significance was determined by the 
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Figure 1. Three novel missense SLC30A2/ZnT2 mutations in Japanese mothers of 
transient neonatal zinc deficient infants. (a) Schematic of SLC30A2/ZnT2 and positions 
of mutations found in this study. Three novel missense mutations, c.838G>A in exon 6, 
c.935C>T in exon 7, and c.1063G>C in exon 8, were identified in three mothers. (b) 
Electropherograms showing the three novel SLC30A2/ZnT2 mutations. The c.838G>A 
mutation (left panel) was found at the 3′ end of exon 6, and thus the last G or A 
nucleotide in exon 6 and the first GG nucleotides in exon 7 generate a GGG or AGG 
codon, respectively. 
 
Figure 2. c.838G>A mutation reduced the splicing efficiency of intron 6 in the ZnT2 
transcript. (a) Schematic representation of ZnT2 transcripts detected in B, in which the 
nucleotide at the end of exon 6 is G (wild-type, WT) or A (mutant). ZnT2 cDNA 
fragments containing the unspliced or the spliced form of intron 6 were amplified. 
Arrows indicate the position of primers used. (b) Results of semi-quantitative RT-PCR. 
PCR products amplified after 33–35 cycles were quantified by densitometric analysis, 
and the relative intensity of the spliced form to the unspliced form is calculated as 0.59 
and 0.15 for WT and mutant transcripts, respectively, at cycle 34. The panel shows 
representative results of triplicate experiments. -, PCR blank. 
 
Figure 3. Evaluation of zinc transport activity of ZnT2 mutants. Zinc transport activity 
of the indicated ZnT2 proteins was determined based on a viability test of zinc-sensitive 
cells incubated in high extracellular zinc concentrations and a fluorescent zinc-selective 
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probe staining. (a) Evaluation of the zinc transport activity of the ZnT2 mutants 
identified in affected mothers using ZnT1−/−MT−/−ZnT4−/− cells. The indicated cells were 
grown in the presence of indicated concentrations of ZnSO4 for 72 h, and the number of 
living cells was measured using the alamarBlue assay (plotted as a percentage of living 
cells at 0 µM ZnSO4 for each group of cells). Parental DT40 cells (■), 
ZnT1−/−MT−/−ZnT4−/− cells (□), and ZnT1−/−MT−/−ZnT4−/− cells stably expressing 
wild-type (WT) ZnT2 (○), G280R (●), T312M (r), or E355Q (▲). (b) Evaluation of 
the zinc transport activity of ZnT2 single nucleotide polymorphism (SNP) mutants 
using ZnT1−/−MT−/−ZnT4−/− cells, as described in (a). Cells stably expressing each of 
the ZnT2 SNP mutants were examined, but only results of the four SNP mutants whose 
zinc transport activity was measured as null are shown. Parental DT40 cells (■), 
ZnT1−/−MT−/−ZnT4−/− cells (□), and ZnT1−/−MT−/−ZnT4−/− cells stably expressing WT 
ZnT2 (○), T181M (●), N189K (r), G233D (▲) or E355K (¯). In (a) and (b), each 
value is the mean ± SD of triplicate experiments. * denotes a significant difference 
between the cells expressing WT ZnT2 and mutant ZnT2 proteins (* P<0.05). (c, d) 
Evaluation of the zinc transport activity of ZnT2 mutants examined in (a) and (b) using 
a fluorescent zinc-selective probe staining. The cells were grown with or without 30 µM 
ZnSO4 for 48 h, and then loaded with Zinpyr-1. After washing, the cells were analyzed 
by flow cytometry. Each histogram represents 50,000 cells and indicates zinc levels 
detected by Zinpyr-1 fluorescence. 
 
Figure 4. Evaluation of protein stability and dimerization of ZnT2 mutants found in 
three Japanese mothers of transient neonatal zinc-deficient infants. (a) Evaluation of 
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protein stability of G280R, T312M, and E355Q ZnT2 mutants. The expression levels of 
the wild-type (WT) () and each mutant () ZnT2 protein at each time point are 
shown. The collection of cells at 8 h was performed when the band intensity of the 
ZnT2 mutant protein was more than 50% at 2 h after cycloheximide treatment, 
compared with that at 0 h. Representative results of immunoblot analysis to monitor 
ZnT2 levels are shown (upper panel). Each value is the mean ± SD of triplicate 
experiments (lower panel). * denotes a significant difference between levels of the WT 
and mutant ZnT2 proteins at each time point (* P<0.05). Tubulin is shown as a loading 
control. (b) Evaluation of dimerization of G280R, T312M, and E355Q ZnT2 mutants. 
Tagged-ZnT2 WT or mutants were immunoprecipitated with antibodies against either 
the FLAG or HA epitopes. The immunoprecipitates were analyzed by immunoblotting 
using antibodies against the FLAG or HA tags. To estimate the amount of tagged ZnT2 
WT and mutant proteins, 10% of each aliquot was subjected to immunoblot analysis 
(input panels). CNX (calnexin) is shown as a loading control. The panels show 
representative results. 
 
Figure 5. Evaluation of protein stability and dimerization of ZnT2 single nucleotide 
polymorphism (SNP) mutants that lack zinc transport activity. (a) Evaluation of the 
protein stability of T181M (rs148861822), N189K (rs200520278), G233D 
(rs201084300), and E355K (rs377192955) was performed as in Figure 4. The 
expression levels of the WT () and each mutant () ZnT2 protein at each time point 
are shown. Representative results of immunoblot analysis to monitor ZnT2 levels are 
shown (upper panel). Each value is the mean ± SD of triplicate experiments (lower 
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panel). * denotes a significant difference between levels of the WT and mutant ZnT2 
proteins at each time point (* P<0.05). Tubulin is shown as a loading control. (b) 
Evaluation of the dimerization of T181M, N189K, G233D, and E355K ZnT2 mutants. 
Tagged-ZnT2 WT or mutants were immunoprecipitated with antibodies against either 
the FLAG or HA epitopes. The immunoprecipitates were analyzed by immunoblotting 
using antibodies against the FLAG or HA tags. To estimate the amount of tagged ZnT2 
WT and mutant proteins, 10% of each aliquot was subjected to immunoblot analysis 
(input panels). The noncontiguous boxed lanes were derived from the same blot. CNX 
is shown as a loading control. The panels show representative results. 
 
Table 1. Single nucleotide polymorphisms (SNPs) in SLC30A2/ZnT2 that cause loss of zinc transport activity 
SNP No. Substitution Protein Exon Global minor allele 
frequencya 
rs148861822 c.542C>T T181M 4 N.A. 
rs200520278 c.567C>A N189K 4 A=0.0002 
rs201084300 c.698G>A G233D 5 A=0.0002 
rs377192955 c.1063G>A E355K 8 N.A. 







Supplemental Table S1. Case reports of TNZD in full-term breast-fed infants published in Japanese journals and abstracts.   




Age of onset 
in infant 







N.D. 6 months N.D. Ishii Y, Nakayama F, Yanabe Y, Horinouchi K. Acquired acrodermatitis 
enteropathica due to low zinc levels in breast milk (Translated from the 





2 months 29 µg/dL 
(4 months) 
Akahori W, Yoshiike T. A case of acrodermatitis enteropathica due to 
low zinc breast milk. J Pediat Dermatol 2007;26:181–5. 
3. 17 µg/dL 
(5 months) 
2 months N.D. 
 
Arai Y, Tsuboi R, Bamba H. A case of zinc deficiency in a breast-fed 
infant due to low zinc levels in breast milk (Translated from the 





13 days 11 µg/dL 
(4 weeks) 
Inamo Y. Acquired zinc-deficiency in the breast of low zinc 





30 days 20 µg/dL 
(2 months) 
Higashi A, Saito A, Nakatani T. Two cases of zinc deficiency in a 
breast-fed infant due to low zinc levels in breast milk (Translated from 






4 months 22 µg/dL 
(7 months) 





3 months 15 µg/dL 
(8 months) 
Hanawa K, Kawachi S, Yamazaki Y, Takata M, Saida T. A case of zinc 
deficiency in a breast-fed infant due to low zinc levels in breast milk 
(Translated from the Japanese title). Rinsho Derma 2009;51:877–9 
8.  16 µg/dL 
(8 months) 
2 months 9 µg/dL 
(8 months) 
Ito M, Ikeda M, Aoki M, Iwasaki T, Kawana S. A case of zinc 
deficiency in a breast-fed infant due to low zinc in the breast milk. J 
Pediatric Dermatol 2008;27:25–7 




5 months 25 µg/dL 
(6 months) 
Okumura S, Terakawa T, Yokomichi S, Miyata A. My experience: Case 
of acquired zinc deficiency in full term breast-fed infant. The Journal of 





3 months N.D. 
 
Ukae S, Yanauchi S, Ito N, Yasuda H. Two cases of zinc deficiency in a 
breast-fed infant due to low zinc levels in breast milk (Translated from 





2 months N.D. 
 
Kuboi I, Nagano N, Nakamura K, et al. Zinc deficiency in a breast-fed 
three month old girl due to low zinc levels in breast milk (Translated 





1 month 12 µg/dL 
(2 months) 
Nishida T, Setoyama M, Narahara S. A case of zinc deficiency in a 
breast-fed infant due to low zinc levels in breast milk (Translated from 





1 month 14 µg/dL 
(3 months) 
Murai M, Ochiai T, Uragami T, Yamazaki R. Zinc deficiency in a 
breast-fed infant due to low zinc levels in breast milk (Translated from 





4 months N.D. 
 
Hashimoto M, Kuramochi A, Nakamura K, Tsuchida T. A case of zinc 
deficiency in a breast-fed infant due to low zinc levels in breast milk 








Isaji M, Futai T. A case of zinc deficiency in a breast-fed infant due to 
low zinc levels in breast milk (Translated from the Japanese title). J Jpn 





10 months 16 µg/dL 
(10 months) 
Tsutsui K, Nakano Y. A case of zinc deficiency in breast-fed sisters due 
to low zinc levels in breast milk (Translated from the Japanese title). The 
Medical Journal of Ishikawa Prefectural Central Hospital 2012;34:47–8 
17.  N.D. 
 
6 months 18 µg/dL 
(7 months) 





1.5 months 22 µg/dL 
(4 months) 
Yasuike R, Okuzawa Y, Tamagawa-Mineoka R, Nakajima H, Katoh N. 
A case of zinc deficiency due to low zinc concentration in maternal 









Seto T, Kobayashi M, Okamoto Y, Sato J, Ito S, Yasuhara T. A case of 
zinc deficiency in a breast-fed infant due to low zinc levels in breast 






4 months 19 µg/dL 
(5 months) 
Kasuga K, Osawa Y, Abe S, et al, Tamura A. A case of zinc deficiency in 
a breast-fed infant due to low zinc levels in breast milk (Translated from 
  the Japanese title). J Jpn Pediatr Soc 2014;118:1396–7 
The cases of Nos. 9 and 18 correspond to patients Nos. 2 and 3 in this manuscript, respectively. a, normal levels, 80±30 µg/dL at 4–6 
months. b, normal levels, 70–120 µg/dL. c, including two infant cases, but one case is a preterm infant (not shown).  
Supplemental Table S2. Symptoms of the transient neonatal zinc deficient infants in this study.   




Age of onset in 
infant 









3 months 13 µg/dL 
(4 months) 
Erythema around the mouth and in the occipital region, diaper 





5 months 25 µg/dL 
(6 months) 
Erythema and blistering particularly in the distal extremities and 






1.5 months 22 µg/dL 
(4 months) 
Erythema on the neck, later erythematous plaque around the 
mouth, extremities, intertriginous regions, external genital. 
Clinical data of patients 2 and 3 were published in domestic Japanese journals (Refs 31 and 32 in the main text). The notation in 
parenthesis in the patient No. column indicates the mutation found in the SLC30A2/ZnT2 gene of the patient’s mother. a, normal levels, 
80±30 µg/dL at 4–6 months. b, normal levels, 70–120 µg/dL. 
 
Supplemental Table S3. SNPs in SLC30A2/ZnT2 that cause minimal defects in the cell viability assay. 
SNP No. Substitution Protein Exon Global minor allele frequencya 
rs144738392 c.21G>C Q7H 1 N.A. 
rs377136186 c.41C>T P14L 1 N.A. 
rs112850383 c.70T>C W24R 2 N.A. 
rs77193883 c.80G>A G27E 2 A=0.0020 
rs199685973 c.90G>T W30C 2 T=0.0002 
rs141752286 c.173G>A G58D 2 N.A. 
rs368255248 c.215G>A R72H 2 N.A. 
rs200712540 c.229G>A A77T 2 A=0.0002 
rs369142908 c.280C>G L94V 3 G=0.0004 
rs370485489 c.464C>T T155M 4 N.A. 
rs199594277 c.490G>A E164K 4 N.A. 
rs199807670 c.559G>T A187S 4 N.A. 
rs112127101 c.596C>G S199C 5 N.A. 
rs201917367 c.599G>A G200D 5 A=0.0004 
rs377645638 c.613C>G H205D 5 N.A. 
rs373747848 c.649G>C V217L 5 N.A. 
rs369755786 c.692G>C S231T 5 N.A. 
rs144129605 c.694A>G M232V 5 N.A. 
rs200039883 c.696G>A M232I 5 A=0.0002 
rs372442248 c.769G>A V257I 6 N.A. 
rs369345160 c.868G>A V290I 7 N.A. 
rs149340896 c.872G>A R291H 7 A=0.0036 
rs151175941 c.895G>A G299R 7 N.A. 
rs372456339 c.967G>A A323T 7 N.A. 
rs149723161 c.988G>A A330T 8 N.A. 
rs145406127 c.1019G>A R340H 8 A=0.0002 
rs144832711 c.1048G>A V350M 8 A=0.0002 
a, 1000 Genome phase 3, genotype data from 2504 worldwide individuals 
 
Supplemental Table S4. Primers used for the RT-PCR analysis presented in Figure 2. 
Primer Sequence (5′ to 3′) 
exon 6 Fw CCTTGACCATCCTGAGAGATGTGATCCTGG 
intron 6 Fw GACACCTGAGGATCAGGAGCCAGCCCTGCA 
exon 8 Rv CTCCGAGTAGTCCTTGATCTGGATGGT 
 
